PI3K/AKT/mTOR Signaling is Involved in (-)-Epigallocatechin-3-Gallate-Induced Apoptosis of Human Pancreatic Carcinoma Cells

被引:70
|
作者
Liu, Shi [1 ]
Wang, Xiao-Jie [2 ]
Liu, Ying [3 ]
Cui, Yun-Fu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China
[2] Heilongjiang Inst Dermatol & Sexually Transmitted, Harbin, Peoples R China
[3] Qiqihar Med Coll, Affiliated Hosp 3, Qiqihar, Peoples R China
来源
AMERICAN JOURNAL OF CHINESE MEDICINE | 2013年 / 41卷 / 03期
关键词
Pancreatic Cancer; (-)-Epigallocatechin-3-Gallate; PI3K; AKT; mTOR; GROWTH-FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; TEA POLYPHENOLS; GREEN TEA; CANCER CHEMOPREVENTION; DIRECT INHIBITION; MCF-7; CELLS; ACTIVATION; SUPPRESSION; PATHWAY;
D O I
10.1142/S0192415X13500444
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
PI3K/AKT/mTOR signaling promotes cell survival, proliferation and progression in cancer cells. Targeting this pathway may lead to the development of novel therapeutic approaches for human cancers. Here, we examined the effects of (-)-epigallocatechin-3-gallate (EGCG) on the PI3K/AKT/mTOR pathway in pancreatic cancer cells, and assessed its therapeutic potential. In this study, the proliferation and apoptosis of PANC-1 cells were examined by MTT assay and flow cytometry, respectively. The expression of genes and proteins involved in the PI3K/AKT/mTOR pathway were measured by RT-PCR and western blotting, respectively. Our results revealed that EGCG dramatically inhibited the proliferation of PANC-1 cells and induced apoptosis simultaneously. Furthermore, it upregulated PTEN mRNA and protein expression levels, as well as downregulating the expression of phospho-AKT and phospho-mTOR. In conclusion, these results suggest that EGCG can suppress proliferation and induce apoptosis of PANC-1 cells in a time- and dose-dependent manner; moreover, EGCG also can upregulate PTEN expression and downregulate the expression of pAKT and p-mTOR to modulate the PI3K/AKT/mTOR signaling pathway.
引用
收藏
页码:629 / 642
页数:14
相关论文
共 50 条
  • [1] PI3K/AKT/mTOR Signaling and Differentiation of Human iPS Cells
    Cross, Alan
    Jaishankar, Amritha
    Brandon, Nicholas
    Wesolowski, Steve
    Burli, Roland
    Hoeppner, Dan
    Kim, Suel-Kee
    Seo, Seungmae
    Shin, Joo Heon
    Colantuoni, Carlo
    Chenoweth, Josh
    Weinberger, Daniel
    McKay, Ron
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S541 - S542
  • [2] The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
    Matsuoka, Tasuku
    Yashiro, Masakazu
    CANCERS, 2014, 6 (03) : 1441 - 1463
  • [3] Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells
    Gupta, S
    Hussain, T
    Mukhtar, H
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 410 (01) : 177 - 185
  • [4] Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells
    Wang, Qing
    Li, Juan
    Gu, Jingli
    Huang, Beihui
    Zhao, Ying
    Zheng, Dong
    Ding, Yan
    Zeng, Lijin
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2009, 41 (12) : 1018 - 1026
  • [5] Compartmentalized PI3K/Akt/mTOR Signaling in Living Cells
    Zhang, Jin
    FASEB JOURNAL, 2015, 29
  • [6] Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma
    Wang, Zhuangqiang
    Cui, Xiaopeng
    Hao, Gaopeng
    He, Jiefeng
    OPEN LIFE SCIENCES, 2021, 16 (01): : 1037 - 1044
  • [7] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [8] (-)-Epigallocatechin-3-gallate stimulates the insulin-responsive PI3K/Akt signaling pathway
    Bartholome, A.
    Sies, H.
    Klotz, L. O.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 81 - 81
  • [9] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [10] Clinical significance of PI3K/Akt/mTOR signaling in gastric carcinoma
    Jung, Eun-Jung
    Suh, Ja Hee
    Kim, Woo Ho
    Kim, Hee Sung
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (05): : 995 - 1007